Genoscience Pharma evaluated their most advanced compound, GNS561, with the chick embryo model.

Genoscience Pharma, a clinical stage biotech focused on Oncology, conducted research on GNS561, a lysosomotropic molecule they developed. With the help of INOVOTION’s chick embryo model, the team could confirm the anticancer activity of their molecule against intrahepatic cholangiocarcinoma and published their results on February 20, 2019.

Once INOVOTION started the study on GNS561, Genoscience Pharma received the in vivo results for their research within 1 month and could publish this article only 10 months later. Supported by GNS561 efficacy in in vivo models (chicken embryo, rats and mice animals models), Genoscience Pharma is currently assessing GNS561’s safety and efficacy through an international Phase1b/2a clinical trial in liver cancer (https://clinicaltrials.gov/ct2/show/NCT03316222).

You can find the publication here: https://link.springer.com/article/10.1007%2Fs10637-019-00741-3